Marshall Wace LLP Cuts Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Marshall Wace LLP lessened its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 47.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,921 shares of the company's stock after selling 38,203 shares during the quarter. Marshall Wace LLP owned approximately 0.06% of Trevi Therapeutics worth $177,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Rosalind Advisors Inc. grew its stake in Trevi Therapeutics by 41.7% in the 4th quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company's stock valued at $4,378,000 after buying an additional 312,500 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Trevi Therapeutics by 120.5% during the fourth quarter. JPMorgan Chase & Co. now owns 221,664 shares of the company's stock worth $913,000 after acquiring an additional 121,147 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company's stock worth $4,223,000 after acquiring an additional 117,418 shares during the period. XTX Topco Ltd purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at $277,000. Finally, Barclays PLC raised its stake in shares of Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company's stock valued at $319,000 after purchasing an additional 61,317 shares during the period. Hedge funds and other institutional investors own 95.76% of the company's stock.

Wall Street Analysts Forecast Growth

TRVI has been the subject of several analyst reports. B. Riley restated a "buy" rating and issued a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Finally, Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Trevi Therapeutics presently has a consensus rating of "Buy" and an average price target of $17.56.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 24.37% of the company's stock.

Trevi Therapeutics Price Performance

TRVI remained flat at $6.60 during midday trading on Friday. The company's stock had a trading volume of 1,429,963 shares, compared to its average volume of 1,160,601. The company has a market cap of $659.29 million, a PE ratio of -15.00 and a beta of 0.62. Trevi Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The firm has a 50 day moving average price of $6.11 and a two-hundred day moving average price of $4.50.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. As a group, equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.